OBJECTIVE： To observe the clinical efficacy and safety of tanshinone ⅡA sulfonate in the treatment of coronary atherosclerotic heart disease （CHD） angina. METHODS： 46 patients with CHD angina were included in efficacy evaluation group， and randomly assigned into trial group （23 cases） and control group （23 cases）； other 45 patients with CHD angina were enrolled into safety evaluation group. All of them were treated with conventional therapy of isosorbide dinitrate， aspirin and β receptor blocker， etc.； trial group was additionally given Tanshinone ⅡA sulfonate injection intravenously， qd， for consecutive 4 d on the basis of routine therapy. The frequency and period of angina attacks， ECG before and after treatment and potential ADR were observed in 2 groups. Safety evaluation group were treated with Tanshinone ⅡA sulfonate injection with same dosage and frequency as trial group， but treatment course was not limited； only the occurrence of ADR was observed in the group. RESULTS： The total effective rates of clinical efficacy and ECG in trial group were 86.96％ and 69.56％， which were significantly higher than the control group （65.22％， 43.48％）， with statistical significance （P＜0.05）. Compared with control group， the frequency and period of angina attacks reduced significantly in trial group after treatment， with statistical significance （P＜0.01）. No ADR was observed in 68 patients treated with intravenous dripping of Tanshinone ⅡA sulfonate injection. CONCLUSIONS： Based on routine therapy， Tanshinone ⅡA sulfonate injection can effectively improve the clinical symptom of CHD angina， with good safety.